IL17C

Summary

IL17C (interleukin 17C, HGNC:5983) is a protein-coding gene on chromosome 16q24.2, encoding Interleukin-17C (Q9P0M4). Cytokine that plays a crucial role in innate immunity of the epithelium, including to intestinal bacterial pathogens, in an autocrine manner.

The protein encoded by this gene is a T cell-derived cytokine that shares the sequence similarity with IL17. This cytokine was reported to stimulate the release of tumor necrosis factor alpha and interleukin 1 beta from a monocytic cell line. The expression of this cytokine was found to be restricted to activated T cells.

Source: NCBI Gene 27189 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 51 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_013278

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5983
Approved symbol	IL17C
Name	interleukin 17C
Location	16q24.2
Locus type	gene with protein product
Status	Approved
Aliases	IL-17C, CX2, IL-21, MGC126884, MGC138401
Ensembl gene	ENSG00000124391
Ensembl biotype	protein_coding
OMIM	604628
Entrez	27189

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 retained_intron

ENST00000244241, ENST00000569133

RefSeq mRNA: 1 — MANE Select: NM_013278 NM_013278

CCDS: CCDS42217

Canonical transcript exons

ENST00000244241 — 3 exons

Exon	Start	End
ENSE00000846930	88638981	88639309
ENSE00001414635	88639814	88640468
ENSE00001530870	88638572	88638647

Expression profiles

Bgee: expression breadth ubiquitous, 137 present calls, max score 96.93.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0333 / max 11.2470, expressed in 9 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155540	0.0333	9

Top tissues by expression

192 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cardiac muscle of right atrium	UBERON:0003379	96.93	gold quality
pancreatic ductal cell	CL:0002079	94.37	silver quality
nasal cavity epithelium	UBERON:0005384	92.02	silver quality
upper arm skin	UBERON:0004263	88.93	gold quality
heart right ventricle	UBERON:0002080	87.69	gold quality
parotid gland	UBERON:0001831	87.68	silver quality
lateral nuclear group of thalamus	UBERON:0002736	86.92	gold quality
kidney epithelium	UBERON:0004819	86.42	gold quality
substantia nigra pars reticulata	UBERON:0001966	86.29	gold quality
superficial temporal artery	UBERON:0001614	86.01	silver quality
vena cava	UBERON:0004087	85.71	silver quality
body of tongue	UBERON:0011876	85.21	silver quality
cerebellar vermis	UBERON:0004720	84.83	silver quality
subthalamic nucleus	UBERON:0001906	83.83	silver quality
sperm	CL:0000019	83.81	silver quality
dorsal plus ventral thalamus	UBERON:0001897	83.73	silver quality
lateral globus pallidus	UBERON:0002476	83.58	silver quality
cardia of stomach	UBERON:0001162	83.38	silver quality
tongue	UBERON:0001723	83.23	silver quality
substantia nigra pars compacta	UBERON:0001965	83.15	silver quality
ventral tegmental area	UBERON:0002691	82.76	silver quality
epithelial cell of pancreas	CL:0000083	82.46	silver quality
pharyngeal mucosa	UBERON:0000355	82.24	silver quality
oocyte	CL:0000023	82.18	gold quality
superior surface of tongue	UBERON:0007371	81.86	silver quality
inferior vagus X ganglion	UBERON:0005363	81.77	silver quality
medulla oblongata	UBERON:0001896	81.26	silver quality
pericardium	UBERON:0002407	80.98	silver quality
superior vestibular nucleus	UBERON:0007227	80.88	silver quality
saphenous vein	UBERON:0007318	80.88	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.70

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NFKB1, NFKB, RELA

miRNA regulators (miRDB)

29 targeting IL17C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-92A-1-5P	98.28	64.51	631
HSA-MIR-124-5P	98.11	67.65	1095
HSA-MIR-3652	97.71	65.43	1890
HSA-MIR-4430	97.47	65.61	1813
HSA-MIR-939-5P	97.10	65.80	1579
HSA-MIR-4689	96.97	65.79	1209
HSA-MIR-1343-5P	96.48	66.06	1506
HSA-MIR-6858-5P	96.05	64.59	1020

Literature-anchored findings (GeneRIF, showing 26)

• expressed in multiple sclerosis brain lesions (PMID:11984595)
• activation of NF-kappaB (p65/p50) is crucial for the TNFalpha-induced stimulation of IL-17C expression in human keratinocytes (PMID:21628458)
• IL-17C is an essential autocrine cytokine that regulates innate epithelial immune responses. (PMID:21993848)
• In our pilot study, we discovered significant changes in methylation patterns of genes IL-7, IL-13, IL-17C and TYK2 between henodialysis patients and healthy subjects (PMID:22506826)
• Data suggest that activation of TLR5 upregulates IL17C expression in cells from intestinal mucosa and colonic adenocarcinoma; IL17C expression is upregulated in intestinal mucosa cells from patients with ulcerative colitis compared with normal cells. (PMID:22994872)
• IL-17C is involved in the innate immune response of respiratory epithelial cells and is suppressed by cigarette smoke. (PMID:23221046)
• Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. (PMID:23359500)
• Interleukin-17C is present in the tissue around aseptic loosened implants. (PMID:23474800)
• Our study provides evidence that Staphylococcus aureus activates NOD2 in keratinocytes, resulting in an increased expression of IL-17C, a mechanism that may be dysregulated in atopic dermatitis. (PMID:23892590)
• IL-17C is an essential epithelial cell-derived cytokine. (PMID:23944933)
• Those carrying rs3748067 CC genotype and C allele had a significantly increased risk for the development of gastric cancer (PMID:25012243)
• CpG methylation is reduced in gingival biopsies of patients with periodontitis (PMID:26472015)
• Inflammatory cell expression of IL-9 and IL-17C were increased in chronic rhinosinusitis, particularly with allergy and asthma. These interleukins may contribute to the pathogenesis of chronic rhinosinusitis with nasal polyps as well as atopy and may serve as therapeutic targets for disease management (PMID:26989880)
• Data indicate that epithelial IL-17C promotes neutrophilic inflammation in the tumor microenvironment and suggest that IL-17C links a pathologic microbiota, as present in COPD patients, with enhanced tumor growth. (PMID:28346430)
• Helicobacter pylori infection was associated with a significant increase in IL-17C expression in gastric mucosa. The role of IL-17C in the pathogenesis of H. pylori-induced diseases remains to be determined. (PMID:28739826)
• Study utilizing human skin samples, cultured primary human and mouse keratinocytes, and mouse disease models indicates that IL-17C is a central mediator of skin inflammation beyond psoriasis and is relevant in particular in atopic dermatitis. (PMID:29474945)
• Patients with acute Anti-neutrophil cytoplasmatic antibody (ANCA)-associated crescentic glomerulonephritis (GN) had significantly elevated serum levels of IL-17C. (PMID:29483158)
• IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer. (PMID:31316109)
• IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology. (PMID:32174926)
• Rhinovirus Induces Basolateral Release of IL-17C in Highly Differentiated Airway Epithelial Cells. (PMID:32232015)
• IL-17C expression and its correlation with pediatric adenoids: a preliminary study. (PMID:33162788)
• IL-17C contributes to NTHi-induced inflammation and lung damage in experimental COPD and is present in sputum during acute exacerbations. (PMID:33411748)
• Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19. (PMID:35479098)
• Th17-Derived Cytokines Synergistically Enhance IL-17C Production by the Colonic Epithelium. (PMID:36130829)
• IL-17C neutralization protects the kidney against acute injury and chronic injury. (PMID:37263138)
• IL-17C is a driver of damaging inflammation during Neisseria gonorrhoeae infection of human Fallopian tube. (PMID:38704381)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il17c	ENSMUSG00000046108
rattus_norvegicus	Il17c	ENSRNOG00000013007
caenorhabditis_elegans		WBGENE00009108

Paralogs (5): IL17A (ENSG00000112115), IL17F (ENSG00000112116), IL17B (ENSG00000127743), IL25 (ENSG00000166090), IL17D (ENSG00000172458)

Protein

Protein identifiers

Interleukin-17C — Q9P0M4 (reviewed: Q9P0M4)

Alternative names: Cytokine CX2

All UniProt accessions (1): Q9P0M4

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that plays a crucial role in innate immunity of the epithelium, including to intestinal bacterial pathogens, in an autocrine manner. Stimulates the production of antibacterial peptides and pro-inflammatory molecules for host defense by signaling through the NF-kappa-B and MAPK pathways. Acts synergically with IL22 in inducing the expression of antibacterial peptides, including S100A8, S100A9, REG3A and REG3G. Synergy is also observed with TNF and IL1B in inducing DEFB2 from keratinocytes. Depending on the type of insult, may have both protective and pathogenic properties, either by maintaining epithelial homeostasis after an inflammatory challenge or by promoting inflammatory phenotype. Enhanced IL17C/IL17RE signaling may also lead to greater susceptibility to autoimmune diseases.

Subunit / interactions. Binds to a heterodimer formed by IL17RA and IL17RE.

Subcellular location. Secreted.

Induction. Up-regulated by bacterial stimuli, including by lipopolysaccharides (LPS) in gut epithelial cell lines. This up-regulation may be mediated by Toll-like receptors TLR2 and TLR5. Up-regulated by various pro-inflammatory cytokines, including TNF, IL1B and IL17F. Up-regulation by IL17A in colon epithelial cells has been observed in some cases, but not in others.

Similarity. Belongs to the IL-17 family.

RefSeq proteins (1): NP_037410* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010345	IL-17_fam	Family
IPR020440	IL-17_chr	Family
IPR029034	Cystine-knot_cytokine	Homologous_superfamily

Pfam: PF06083

UniProt features (6 total): disulfide bond 2, signal peptide 1, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P0M4-F1	81.96	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 129–189, 134–191

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-448424	Interleukin-17 signaling

MSigDB gene sets: 59 (showing top): CREL_01, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, AREB6_03, GOBP_CELL_CELL_SIGNALING, NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON, FOXJ2_01, GOBP_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, AFP1_Q6, GOMF_CYTOKINE_ACTIVITY, GOBP_PROTEIN_K63_LINKED_UBIQUITINATION, FREAC7_01, GOMF_SIGNALING_RECEPTOR_BINDING

GO Biological Process (3): inflammatory response (GO:0006954), cell surface receptor signaling pathway (GO:0007166), cell-cell signaling (GO:0007267)

GO Molecular Function (1): cytokine activity (GO:0005125)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
defense response	1
signal transduction	1
cell communication	1
signaling	1
receptor ligand activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

726 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL17C	IL17RE	Q8NFR9	996
IL17C	IL17RB	Q9NRM6	993
IL17C	IL17RA	Q96F46	982
IL17C	IL17RC	Q8NAC3	951
IL17C	IL17RD	Q8NFM7	805
IL17C	IL22	Q9GZX6	754
IL17C	IL33	O95760	728
IL17C	CNR2	P34972	701
IL17C	CXCL8	P10145	686
IL17C	IL25	Q9H293	684
IL17C	IL1B	P01584	683
IL17C	TNF	P01375	677
IL17C	IL13	P35225	659
IL17C	CCL11	P50877	656
IL17C	IL5	P05113	639

IntAct

0 interactions, top by confidence:

ESM2 similar proteins: A6N6I9, B0VXV3, B0VXV4, C0K3N1, O40633, O46526, P00683, P0DW98, P24916, P34129, P49764, P50412, P67861, P67862, P67863, Q16552, Q330K6, Q3HRV3, Q3S2X5, Q5BJ95, Q60I29, Q61453, Q62386, Q63434, Q687Y7, Q6J936, Q7TNI7, Q8K4C5, Q8SPN3, Q8SPN4, Q8VD87, Q8VHH8, Q90X23, Q90X24, Q96PD4, Q9D244, Q9P0M4, Q9QXT6, Q9QYX2, Q9QYX3

Diamond homologs: A6N6I9, O40633, P24916, Q16552, Q5BJ95, Q60I29, Q61453, Q62386, Q687Y7, Q7TNI7, Q8K4C5, Q8TAD2, Q8VHH8, Q96PD4, Q9EQI6, Q9H293, Q9P0M4, Q9QXT6, Q9UHF5, A9XE49

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	42
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
2685587	GRCh37/hg19 16q24.2-24.3(chr16:88067200-89460290)x1	Pathogenic

SpliceAI

273 predictions. Top by Δscore:

Variant	Effect	Δscore
16:88638705:G:GT	donor_gain	1.0000
16:88639812:A:AG	acceptor_gain	1.0000
16:88639812:AGT:A	acceptor_gain	1.0000
16:88639812:AGTGT:A	acceptor_gain	1.0000
16:88639813:G:GA	acceptor_gain	1.0000
16:88639813:GT:G	acceptor_gain	1.0000
16:88639813:GTG:G	acceptor_gain	1.0000
16:88639813:GTGT:G	acceptor_gain	1.0000
16:88639813:GTGTG:G	acceptor_gain	1.0000
16:88638687:G:GT	donor_gain	0.9900
16:88638706:A:T	donor_gain	0.9900
16:88638709:GGC:G	donor_gain	0.9900
16:88639809:CGCAG:C	acceptor_loss	0.9900
16:88639810:GCA:G	acceptor_loss	0.9900
16:88638705:G:T	donor_gain	0.9800
16:88639310:G:GG	donor_gain	0.9800
16:88639804:C:CA	acceptor_gain	0.9800
16:88639809:C:A	acceptor_gain	0.9800
16:88638645:ACGG:A	donor_loss	0.9700
16:88638646:CGGTG:C	donor_loss	0.9700
16:88638647:GGTGA:G	donor_loss	0.9700
16:88638648:G:GG	donor_gain	0.9700
16:88638648:GTGA:G	donor_loss	0.9700
16:88638649:T:A	donor_loss	0.9700
16:88638701:C:T	donor_gain	0.9700
16:88638730:G:GT	donor_gain	0.9700
16:88638650:GAGCC:G	donor_loss	0.9600
16:88639307:CCGGT:C	donor_loss	0.9600
16:88639308:CGG:C	donor_loss	0.9600
16:88639309:GGTGA:G	donor_loss	0.9600

AlphaMissense

1243 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:88639301:G:C	W109C	0.995
16:88639301:G:T	W109C	0.995
16:88639863:T:A	C129S	0.990
16:88639864:G:C	C129S	0.990
16:88639921:C:T	S148F	0.990
16:88639299:T:A	W109R	0.988
16:88639299:T:C	W109R	0.988
16:88640043:T:A	C189S	0.988
16:88640044:G:C	C189S	0.988
16:88640050:G:A	C191Y	0.986
16:88639858:C:A	A127D	0.985
16:88639878:T:A	C134S	0.985
16:88639879:G:C	C134S	0.985
16:88639863:T:C	C129R	0.984
16:88639839:C:T	P121S	0.983
16:88639840:C:A	P121Q	0.981
16:88640032:T:A	V185D	0.980
16:88640043:T:C	C189R	0.979
16:88639834:G:C	R119P	0.977
16:88640049:T:A	C191S	0.977
16:88640050:G:C	C191S	0.977
16:88640050:G:T	C191F	0.977
16:88639833:C:A	R119S	0.976
16:88639879:G:A	C134Y	0.976
16:88640038:T:A	V187D	0.976
16:88639865:C:G	C129W	0.975
16:88639869:T:A	C131S	0.975
16:88639870:G:C	C131S	0.975
16:88639921:C:A	S148Y	0.975
16:88640049:T:C	C191R	0.975

dbSNP variants (sampled 300 via entrez): RS1000842261 (16:88637961 G>A,C), RS1001295656 (16:88637816 G>A), RS1002131183 (16:88638378 G>A), RS1002350676 (16:88640402 C>T), RS1003687667 (16:88638920 T>C), RS1003797957 (16:88639906 C>T), RS1003912717 (16:88639990 C>A,T), RS1004220319 (16:88637681 T>C), RS1004916398 (16:88639261 T>A,G), RS1005513235 (16:88640750 T>C), RS1005683566 (16:88638613 C>T), RS1006042040 (16:88640926 A>G), RS1006082411 (16:88639403 C>A,G,T), RS1007801943 (16:88640227 C>G,T), RS1008254899 (16:88639690 C>G,T)

Disease associations

OMIM: gene MIM:604628 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003479_9	Hair color	1.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5483004 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

73 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.85	IC50	1.4	nM	CHEMBL5414591
8.85	IC50	1.4	nM	CHEMBL5400846
8.77	IC50	1.7	nM	CHEMBL5422103
8.77	IC50	1.7	nM	CHEMBL5619911
8.54	IC50	2.9	nM	CHEMBL5438651
8.52	IC50	3	nM	CHEMBL5414048
8.48	IC50	3.3	nM	CHEMBL5419043
8.38	IC50	4.2	nM	CHEMBL5430856
8.36	IC50	4.4	nM	CHEMBL5400846
8.35	IC50	4.5	nM	CHEMBL5430936
8.31	IC50	4.9	nM	CHEMBL5401395
8.27	IC50	5.4	nM	CHEMBL5394125
8.26	IC50	5.5	nM	CHEMBL5417150
8.25	IC50	5.6	nM	CHEMBL5618410
8.21	IC50	6.2	nM	CHEMBL5423170
8.20	IC50	6.3	nM	CHEMBL5424668
8.19	IC50	6.4	nM	CHEMBL5410548
8.15	IC50	7	nM	CHEMBL5439897
8.10	IC50	7.9	nM	CHEMBL5414220
8.09	IC50	8.1	nM	CHEMBL5415927
8.05	IC50	9	nM	CHEMBL5415066
8.04	IC50	9.2	nM	CHEMBL5420382
8.02	IC50	9.6	nM	CHEMBL5427574
7.98	IC50	10.4	nM	CHEMBL5412206
7.95	IC50	11.3	nM	CHEMBL5422995
7.93	IC50	11.8	nM	CHEMBL5407942
7.92	IC50	12	nM	CHEMBL5437605
7.92	IC50	12	nM	CHEMBL5417062
7.82	IC50	15	nM	CHEMBL5620040
7.58	IC50	26.4	nM	CHEMBL5439089
7.33	IC50	47	nM	CHEMBL5618612
7.31	IC50	48.8	nM	CHEMBL5396605
7.17	IC50	68	nM	CHEMBL5619116
7.14	IC50	73	nM	CHEMBL5619950
7.08	IC50	83	nM	CHEMBL5619039
7.07	IC50	86	nM	CHEMBL5619162
7.05	IC50	89	nM	CHEMBL5618090
6.97	IC50	108	nM	CHEMBL5620164
6.94	IC50	116	nM	CHEMBL5618934
6.92	IC50	119	nM	CHEMBL5618722
6.78	IC50	166	nM	CHEMBL5428650
6.77	IC50	171	nM	CHEMBL5439961
6.75	IC50	180	nM	CHEMBL5411068
6.68	IC50	211	nM	CHEMBL5428530
6.59	IC50	254	nM	CHEMBL5403673
6.59	IC50	254	nM	CHEMBL5618262
6.54	IC50	288	nM	CHEMBL5421972
6.48	IC50	328	nM	CHEMBL5439819
6.40	IC50	400	nM	CHEMBL5396237
6.38	IC50	414	nM	CHEMBL5409554

PubChem BioAssay actives

73 with measured affinity, of 112 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0014	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0014	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0017	uM
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0017	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12-[(1S)-1-hydroxyethyl]-24-(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0029	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-benzyl-36-[(2S)-butan-2-yl]-12-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0030	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-12,24-bis(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0033	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0042	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0045	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33R,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-5-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0049	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-(3-carbamimidamidopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-5-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0054	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0055	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-24-[(2R)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0056	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-benzyl-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-12,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0062	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-12-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0063	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0064	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12,24,27-tris(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0070	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-(3-amino-3-oxopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0079	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0081	uM
(6S,9S,12S,15S,18S,21S,24S,27S,30S,36R,42S,45S)-N-(2-amino-2-oxoethyl)-12-(hydroxymethyl)-6,15,18,21,30-pentakis[(4-hydroxyphenyl)methyl]-27-(1H-imidazol-4-ylmethyl)-9,42-bis(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,38,41,44-tetradecaoxo-24-propan-2-yl-34-thia-1,4,7,10,13,16,19,22,25,28,31,37,40,43-tetradecazabicyclo[43.3.0]octatetracontane-36-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0090	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-12,27-dimethyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0092	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0096	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0104	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0113	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-2-ylmethyl)-24-methyl-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0118	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,12,21-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0120	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0120	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0150	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,24-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0264	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0470	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,24,36-tetrakis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0488	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0680	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0730	uM
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0830	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-36-(2-carboxyethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0860	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-36-(4-aminobutyl)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0890	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27,36-bis(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1080	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-27-(4-aminobutyl)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1160	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,36,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1190	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1660	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-33-benzyl-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,42-tris[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1710	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-12-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1800	uM
(3R,9S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2110	uM
3-[(4S,7S,10S,13S,16S,19S,22S,25S,28S,34S,37S,43R)-43-[(2-amino-2-oxoethyl)carbamoyl]-19-(3-carbamimidamidopropyl)-4,13,16,28-tetrakis[(4-hydroxyphenyl)methyl]-7,10-bis(1H-imidazol-4-ylmethyl)-22-methyl-25,37-bis(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38,41-tetradecaoxo-1-thia-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecazacyclotetratetracont-34-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2540	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-24-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.2540	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-24-[(1R)-1-hydroxyethyl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2880	uM
(3R,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-15,24-bis(3-amino-3-oxopropyl)-21,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9-(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.3280	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4000	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-39-(1H-imidazol-5-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-24-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4140	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-9,24-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-21-(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4220	uM

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Resveratrol	affects cotreatment, decreases expression	2
Plant Extracts	affects cotreatment, decreases expression, decreases reaction, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
bisphenol A	increases expression	1
beta-lapachone	increases expression	1
lipopolysaccharide, E. coli O26-B6	increases expression	1
brevetoxin 2	increases expression	1
Acetaminophen	decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cannabidiol	decreases reaction, increases expression	1
Cannabinoids	decreases reaction, increases abundance, increases expression	1
Folic Acid	decreases expression	1
Valproic Acid	increases methylation	1
Particulate Matter	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5363915	Binding	Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	PepScaf: Harnessing Machine Learning with In Vitro Selection toward De Novo Macrocyclic Peptides against IL-17C/IL-17RE Interaction. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.